BPH investee Cortical files new patent application
BPH Energy Ltd (ASX:BPH) investee company Cortical Dynamics Ltd has filed a new international patent application.
BPH has a net interest of 16% in Cortical, an Australian based medical device technology company that has developed a next generation Brain Function Monitor.
Cortical’s core-product is the Brain Anaesthesia Response (BAR) monitor, developed with the objective of better detecting the effect of anaesthetic agents on brain activity, aiding anaesthetists in keeping patients optimally anaesthetised.
The patent application for ‘Apparatus and process for measuring brain activity “ has now been given International (PCT) Patent Application No. PCT/AU2020/050535.
This comes on the back of news last week that Cortical had begun the filing process for its BARM technology (brain anaesthesia response monitor) in the US with the filing of an FDA 510K.
FDA approval is a necessary precursor for sales of BARM to commence in the US.
Cortical has developed an extensive patent portfolio encapsulating the BARM, providing critical patent protection across a number of key brain monitoring markets.
Corticals’ competitive advantage is underpinned by a strong patent position covered by five patent families and 22 granted patents.
Cortical has patents awarded in Australia, New Zealand, Japan, the People’s Republic of China, Europe and the United States.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.